We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Abbott (ABT - Free Report) is expected to reveal quarterly earnings of $1.14 per share, indicating an increase of 4.6% compared to the year-ago period. Analysts forecast revenues of $11.02 billion, representing an increase of 6.4% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Abbott metrics that are commonly monitored and projected by Wall Street analysts.
Based on the collective assessment of analysts, 'Net sales- Nutrition' should arrive at $2.01 billion. The estimate suggests a change of -6.3% year over year.
The consensus among analysts is that 'Net sales- Medical Devices- Diabetes Care' will reach $2.10 billion. The estimate suggests a change of +15% year over year.
Analysts expect 'Net sales- Diagnostics' to come in at $2.09 billion. The estimate indicates a change of +1.8% from the prior-year quarter.
The consensus estimate for 'Net sales- Established Pharmaceuticals' stands at $1.40 billion. The estimate indicates a year-over-year change of +11.5%.
The collective assessment of analysts points to an estimated 'Net sales- Diagnostics- U.S.' of $861.27 million. The estimate indicates a year-over-year change of -1.1%.
Analysts predict that the 'Net sales- Diagnostics- International' will reach $1.23 billion. The estimate suggests a change of +3.9% year over year.
Analysts' assessment points toward 'Net sales- Nutrition- International' reaching $1.17 billion. The estimate indicates a year-over-year change of -2.1%.
According to the collective judgment of analysts, 'Net sales- Nutrition- U.S.' should come in at $853.76 million. The estimate indicates a change of -10.6% from the prior-year quarter.
Analysts forecast 'Net sales- Medical Devices- Neuromodulation- International' to reach $58.73 million. The estimate indicates a change of +12.9% from the prior-year quarter.
The average prediction of analysts places 'Net sales- Medical Devices- Rhythm Management- U.S.' at $337.94 million. The estimate suggests a change of +11.2% year over year.
It is projected by analysts that the 'Net sales- Medical Devices- Rhythm Management- International' will reach $311.46 million. The estimate suggests a change of +10.8% year over year.
The combined assessment of analysts suggests that 'Net sales- Medical Devices- Structural Heart- U.S.' will likely reach $302.90 million. The estimate indicates a year-over-year change of +7.4%.
Shares of Abbott have experienced a change of -7.2% in the past month compared to the +0.6% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), ABT is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Unlocking Q1 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
The upcoming report from Abbott (ABT - Free Report) is expected to reveal quarterly earnings of $1.14 per share, indicating an increase of 4.6% compared to the year-ago period. Analysts forecast revenues of $11.02 billion, representing an increase of 6.4% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Abbott metrics that are commonly monitored and projected by Wall Street analysts.
Based on the collective assessment of analysts, 'Net sales- Nutrition' should arrive at $2.01 billion. The estimate suggests a change of -6.3% year over year.
The consensus among analysts is that 'Net sales- Medical Devices- Diabetes Care' will reach $2.10 billion. The estimate suggests a change of +15% year over year.
Analysts expect 'Net sales- Diagnostics' to come in at $2.09 billion. The estimate indicates a change of +1.8% from the prior-year quarter.
The consensus estimate for 'Net sales- Established Pharmaceuticals' stands at $1.40 billion. The estimate indicates a year-over-year change of +11.5%.
The collective assessment of analysts points to an estimated 'Net sales- Diagnostics- U.S.' of $861.27 million. The estimate indicates a year-over-year change of -1.1%.
Analysts predict that the 'Net sales- Diagnostics- International' will reach $1.23 billion. The estimate suggests a change of +3.9% year over year.
Analysts' assessment points toward 'Net sales- Nutrition- International' reaching $1.17 billion. The estimate indicates a year-over-year change of -2.1%.
According to the collective judgment of analysts, 'Net sales- Nutrition- U.S.' should come in at $853.76 million. The estimate indicates a change of -10.6% from the prior-year quarter.
Analysts forecast 'Net sales- Medical Devices- Neuromodulation- International' to reach $58.73 million. The estimate indicates a change of +12.9% from the prior-year quarter.
The average prediction of analysts places 'Net sales- Medical Devices- Rhythm Management- U.S.' at $337.94 million. The estimate suggests a change of +11.2% year over year.
It is projected by analysts that the 'Net sales- Medical Devices- Rhythm Management- International' will reach $311.46 million. The estimate suggests a change of +10.8% year over year.
The combined assessment of analysts suggests that 'Net sales- Medical Devices- Structural Heart- U.S.' will likely reach $302.90 million. The estimate indicates a year-over-year change of +7.4%.
View all Key Company Metrics for Abbott here>>>Shares of Abbott have experienced a change of -7.2% in the past month compared to the +0.6% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), ABT is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .